This technology is a polymer-based modification that protects bioprosthetic heart valves from biochemical degeneration and improves long-term performance.
Bioprosthetic heart valves (BHV), typically made from crosslinked bovine or porcine tissue, are widely used as replacement valves for patients with severe heart valve disease. However, these biomaterials progressively degrade over time due to calcification and accumulation of advanced glycation end-products (AGEs) and serum proteins. This biochemical remodeling increases tissue crosslinking, stiffens valve leaflets, and promotes inflammatory signaling, ultimately leading to structural valve degeneration and device failure. Therefore, new strategies are needed to prevent serum protein- and glycation-mediated degeneration and to improve the long-term durability of BHVs.
This technology modifies bioprosthetic tissue with poly(2-oxazoline) (POZ), a biocompatible polymer, to limit serum protein infiltration and prevent subsequent prosthesis dysfunction. When covalently attached to BHV leaflets, POZ reduces tissue oxidation, serum protein uptake, and inflammation associated with structural valve degeneration. By limiting these degradation pathways, this modification may reduce AGEs accumulation in vivo and extend the functional lifespan of bioprosthetic valves.
Patent Pending (US20230048369)
IR CU20085, IR CU19082, IR CU19243, IR CU20078, IR CU22171
Licensing Contact: Jerry Kokoshka